Positive Press Coverage Somewhat Unlikely to Impact Veracyte (VCYT) Stock Price

News coverage about Veracyte (NASDAQ:VCYT) has been trending positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Veracyte earned a coverage optimism score of 0.33 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.7466713729572 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:

A number of analysts have recently commented on VCYT shares. Piper Jaffray Companies reaffirmed a “hold” rating and issued a $5.40 price target on shares of Veracyte in a research report on Thursday, March 1st. ValuEngine lowered Veracyte from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Zacks Investment Research lowered Veracyte from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Veracyte presently has an average rating of “Hold” and a consensus target price of $10.78.

VCYT stock traded down $0.09 during midday trading on Wednesday, hitting $6.15. 58,456 shares of the stock traded hands, compared to its average volume of 110,072. The stock has a market cap of $211.23, a price-to-earnings ratio of -6.76 and a beta of 1.61. The company has a quick ratio of 4.04, a current ratio of 4.49 and a debt-to-equity ratio of 0.68. Veracyte has a 12-month low of $5.23 and a 12-month high of $9.80.

ILLEGAL ACTIVITY NOTICE: This article was originally posted by BBNS and is owned by of BBNS. If you are viewing this article on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The correct version of this article can be viewed at https://baseballnewssource.com/2018/03/22/veracyte-vcyt-earns-media-impact-score-of-0-33/1925031.html.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.

Insider Buying and Selling by Quarter for Veracyte (NASDAQ:VCYT)

Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Tampa Bay Starting Relievers In Place of Starters
Tampa Bay Starting Relievers In Place of Starters
Teen Juan Soto Hits Home Run in First At-Bat
Teen Juan Soto Hits Home Run in First At-Bat
Ji-Man Choi Receives Another Chance in Milwaukee
Ji-Man Choi Receives Another Chance in Milwaukee
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old


Leave a Reply

 
© 2006-2018 BBNS.